Amarin Corp Plc (AMRN)

[anfla]

Yes but they won’t be indirectly infringing. The label doesn’t indicate off label prescription. Medicare in no way will indicate to pharmacists that they should prescribe generic Vascepa specifically - so again you can’t sue them. The actual pharmacists won’t know the indication so they won’t be aware they are possible infringing by swapping brand name for generic. So there’s no case here. If Amarin could just keep suing, the stock wouldn’t have dropped. They need to win the appeal